Avalo Therapeutics Inc

-0.03 (-1.48%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)223.52M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.9 Million
Adjusted EPS-$0.16
See more estimates
10-Day MA$2.11
50-Day MA$2.24
200-Day MA$2.80
See more pivots

Avalo Therapeutics Inc Stock, NASDAQ:AVTX

540 Gaither Road, Suite 400, Rockville, Maryland 20850
United States of America
Phone: +1.410.522.8707
Number of Employees: 32


Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.